Chemed Corp reported significant second-quarter growth, achieving a 43.7% rise in GAAP diluted earnings per share to $5.13. Driven by strong performance from its VITAS Healthcare unit, this growth positions the firm favorably for continued investment appeal.
Key Highlights
- Adjusted diluted EPS surged to $6.06, exceeding consensus estimates of $5.66.
- The VITAS segment saw net patient revenue rise 11.9%.
- Chemed's market cap stands at approximately $6.9 billion, with shares up 22.1% year-to-date.
Chemed Corp (NYSE: CHE) recorded strong second-quarter results, highlighted by a remarkable 43.7% rise in GAAP diluted earnings per share (EPS) to $5.13. The company also announced an adjusted diluted EPS of $6.06, surpassing the consensus estimate of $5.66, solidifying its position in the healthcare sector. The strong earnings were buoyed primarily by the performance of VITAS Healthcare, which is the nation’s largest provider of end-of-life care, bolstering investor confidence in Chemed's trajectory.
Solid Revenue Growth
For the quarter ending June 30, 2026, Chemed reported consolidated revenue of $673.3 million, reflecting an increase of 8.8% year-over-year. The segment experienced significant operational momentum with an average daily census rising to 23,687 patients, a 6.1% increase compared to the same period last year. This growth trend is also attributable to higher Medicare reimbursement rates, which rose approximately 2.4%.
However, challenges such as acuity mix shifts contributed to a decline in growth. Such dynamics highlight the competitive environment Chemed operates within and the pressures affecting patient care deliveries that can impact revenues.
VITAS Healthcare Drives Performance
VITAS Healthcare's strong performance is important to Chemed's overall financial health, with net income rising to $61.3 million, marking a striking 60.5% increase year-over-year. Adjusted EBITDA for VITAS, excluding Medicare Caps, reached $80.6 million, up 20.6% compared to the prior year, showcasing the effectiveness of cost management alongside revenue growth. The company accrued only $500,000 in Medicare Cap billing limitations this quarter, compared to $16.4 million last year, which indicates a healthier financial margin.
Higher revenue per patient per day, recorded at $209.98, also surpassed last year's averages, further reinforcing VITAS' leading position in the hospice care industry. This growth is integral to Chemed's strategy, indicating a recovering demand for hospice services that may translate into sustained profitability. In addition, the stock has risen by 11.7% over the last month, indicating strong investor sentiment following the release of the strong quarterly results.
Market capitalization for Chemed currently stands at about $6.9 billion. Comparatively, peers in the sector show mixed performance with LH little changed, while DVA is up 0.3% today. These metrics suggest that while Chemed is thriving, the broader market environment remains competitive as healthcare services adapt to regulatory changes and market demands.
Future Outlook and Guidance
Following the positive results, Chemed has raised its full-year guidance significantly, projecting adjusted earnings per diluted share, a reflection of both the outperformance of VITAS and strategic share repurchases that have reduced outstanding shares significantly. Operational improvements and the anticipation of continued growth patterns in hospice care position Chemed favorably moving forward. The company will provide further insights during its conference call scheduled for July 29, 2026.
Investors should monitor this development closely as it may signal sustained performance and potential for accelerated returns.
Peers Moving on This News
- Labcorp Holdings Inc (LH) little changed
- DaVita Inc (DVA) up 0.3%
Analysis based on the Form 8-K filed 28 July 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...